Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea

Bribeche, Mohamed Ridha; Fedotov, V. P.; Gladichev, V. V.; Pukhalskaya, D. M.; Kolitcheva, Natalia L.

doi:10.1111/ijd.12552

Cited by 14 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One hundred and fifty‐two studies were included (eight references report on two studies), comprising 20 944 participants (mean age 48·6 years). More women ( n = 12 575) than men ( n = 5313) were included; sex was not reported in 3056.…”

Section: Resultsmentioning

confidence: 99%

Interventions for rosacea based on the phenotype approach: an updated systematic review includingGRADEassessments

et al. 2019

View full text Add to dashboard Cite

SummaryBackgroundRosacea is a common chronic facial dermatosis. Classification of rosacea has evolved from subtyping to phenotyping.ObjectivesTo update our systematic review on interventions for rosacea.MethodsWe searched CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index and ongoing trials registers (March 2018) for randomized controlled trials. Study selection, data extraction, risk‐of‐bias assessment and analyses were carried out independently by two authors. Grading of Recommendations, Assessment, Development and Evaluations (GRADE) was used to assess certainty of evidence.ResultsWe included 152 studies (46 were new), comprising 20 944 participants. Topical interventions included brimonidine, oxymetazoline, metronidazole, azelaic acid, ivermectin and other topical treatments. Systemic interventions included oral antibiotics, combinations with topical treatments or other systemic treatments. Several studies evaluated laser or light‐based treatment. We present the most current evidence for rosacea management based on a phenotype‐led approach.ConclusionsFor reducing temporarily persistent erythema there was high‐certainty evidence for topical brimonidine and moderate certainty for topical oxymetazoline; for erythema and mainly telangiectasia there was low‐to‐moderate‐certainty evidence for laser and intense pulsed light therapy. For reducing papules/pustules there was high‐certainty evidence for topical azelaic acid and topical ivermectin; moderate‐to‐high‐certainty evidence for doxycycline 40 mg modified release (MR) and isotretinoin; and moderate‐certainty evidence for topical metronidazole, and topical minocycline and oral minocycline being equally effective as doxycycline 40 mg MR. There was low‐certainty evidence for tetracycline and low‐dose minocycline. For ocular rosacea, there was moderate‐certainty evidence that oral omega‐3 fatty acids were effective and low‐certainty evidence for ciclosporin ophthalmic emulsion and doxycycline.

show abstract

Section: Resultsmentioning

confidence: 99%

Interventions for rosacea based on the phenotype approach: an updated systematic review includingGRADEassessments

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Many clinical trials in rosacea still recruit patients using subtype‐based inclusion criteria and assess treatment outcomes according to those subtypes (for example, using the NRS Rosacea Clinical Scorecard) . However, although some more recent studies have still recruited patients by subtype, they have assessed therapeutic response by change in individual features . This is a positive step towards a phenotype approach.…”

Section: Resultsmentioning

confidence: 99%

“…19 However, although some more recent studies have still recruited patients by subtype, they have assessed therapeutic response by change in individual features. [24][25][26][27] This is a positive step towards a phenotype approach.…”

Section: Challenges and Recommendations For Interventional Researchmentioning

confidence: 99%

Applying the phenotype approach for rosacea to practice and research

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The characteristics and results of the 58 studies (two references reported on two studies) included in the previous version of this Cochrane review were summarized earlier in this journal and can also be found in File S2 (see Supporting Information) . The characteristics and results of the 40 newly identified studies (37 references, as three references reported on two studies) are presented in File S3 (see Supporting Information) …”

Section: Resultsmentioning

confidence: 99%

Interventions for rosacea: abridged updated Cochrane systematic review including GRADE assessments

Zuuren

Fedorowicz

2015

Br J Dermatol

View full text Add to dashboard Cite

Rosacea is a common chronic facial dermatosis. This update of our Cochrane review on interventions for rosacea summarizes the evidence, including Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group assessments, of the effects of the currently available treatments. Searches included the following: Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane Library, MEDLINE, EMBASE, LILACS and the Science Citation Index, and ongoing trials registries (July 2014). We included 106 randomized controlled trials (RCTs) with 13 631 participants, a more than 80% increase since the last update in 2011. Pooling of data was feasible for a few outcomes, for topical metronidazole and azelaic acid and both appeared to be more effective than placebo (moderate and high-quality evidence, respectively). Topical ivermectin was more effective than placebo based on two studies (high-quality evidence), and slightly more effective than metronidazole in one study. Brimonidine was more effective than vehicle in reducing erythema in rosacea (high-quality evidence). Ciclosporin ophthalmic emulsion was effective for ocular rosacea (low-quality evidence). For oral treatments there was moderate-quality evidence for the effectiveness of tetracycline based on two old studies, and high-quality evidence for doxycycline 40 mg compared with placebo according to physician assessments. One study at high risk of bias demonstrated equivalent effectiveness for azithromycin and doxycycline 100 mg. Minocycline 45 mg may be effective for papulopustular rosacea (low-quality evidence). Low-dose isotretinoin appeared to be slightly more effective than doxycycline 50-100 mg (high-quality evidence). Laser and light-based therapies for erythema in rosacea were effective (low-quality evidence). Further RCTs are required for ocular rosacea.

show abstract

Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea

Abstract: Use of 3% PZQ ointment twice daily for 12 weeks resulted in significantly better effects than a placebo treatment in improving rosacea and the patient's quality of life.

Cited by 14 publications

References 13 publications

Interventions for rosacea based on the phenotype approach: an updated systematic review includingGRADEassessments

Interventions for rosacea based on the phenotype approach: an updated systematic review includingGRADEassessments

Applying the phenotype approach for rosacea to practice and research

Interventions for rosacea: abridged updated Cochrane systematic review including GRADE assessments

Contact Info

Product

Resources

About